Surgery for weight loss exceeds popular Ozimpic treatment in a new shocking comparison

It was shown that weight loss surgery is five times more effective than the weekly injections of popular agonists of the GLP-1 receiver, including the semagglutide (such as Ozempic) and the tirzepatido (such as Mounjaro).

The finding comes from a recent study presented this week in the American Society of Metabolic and Bariatric Surgery (ASBS).

The researchers analyzed data from electronic medical records “of the real world” of 51,085 patients in Nyu Langone Health and NYC Health +hospitals.

The stylists and the medical expert confirm the temporary loss of hair that affects Ozempic users

All patients had a body mass index (BMI) of at least 35.

They had undergone bariatric surgery (manga gastrectomy or gastric bypass roux en-and) or prescribed injectable or tirzepatida between 2018 and 2024.

(Manga gastrectomy reduces stomach size to help obese patients lose weight; gastric bypass implies redirecting the digestive tract to avoid a portion of the small intestine, according to Mayo Clinic).

Patients who had one of the bariatric surgeries had lost an average of 58 pounds two years later, while those who had taken a GLP-1 prescribed medication for at least six months lost 12 pounds, the researchers found.

Low calorie diets linked to a surprising mental health effect, shows new research

The surgical results marked a total weight loss of 24% compared to 4.7% for injectable medications, according to the study press release.

Those who took the GLP-1 medicine for a full year showed more weight loss (7%), but it was still less than those who had undergone one of the surgeries.

These results differ from the results of clinical trials.

“Clinical trials show a weight loss between 15% and 21% for LPG-1, but this study suggests that weight loss in the real world is considerably lower even for patients who have active prescriptions for a whole year,” said the main study author Avery Brown, MD, surgical resident of Nyu Langone Health, in the press release.

Click here to get the News application

According to Brown, up to 70% of patients with LPG-1 recipes can suspend treatment within a year.

“Patients with LPG-1 may need to adjust their expectations, adhere more to treatment or opt for metabolic and bariatric surgery to achieve the desired results,” he advised.

The surgical results marked a total weight loss of 24% compared to 4.7% for injectable medications.

In future studies, researchers plan to explore strategies to improve the results for patients who take LPG-1 and identify which patients are better candidates for surgery versus injectable medications, according to the statement.

The prevalence of GLP-1 drugs is greater than bariatric surgeries. Studies show that about 12% of Americans have taken a LPG-1, while 6% are currently taking them.

Click here to register in our health newsletter

However, more than half of the patients stop taking them after a year, and 72% leave them after two years, according to the investigation.

Only about 1% of patients who meet the criteria for metabolic and bariatric surgeries underwent one of those procedures in 2023, according to ASBB.

The study received subsidy funds from the National Center for the Advance of Translation Sciences in the National Health Institutes (NIH).

Novo Nordisk, manufacturer of Ozempic and Wegovy, rejected a request for comments.

For more health articles, visit www.Newsnews.com/health

News Digital also contacted researchers already Eli Lilly, manufacturer of Mounjaro and Zepbound.